Cayman Tetrahydrocoptisine; Qty- 10; Size-10 Mg

Fenebrutinib is an inhibitor of Bruton’s tyrosine kinase (BTK; K_is = 0.91, 1.6, 1.3, 12.6, and 3.4 nM for wild-type BTK, BTK^C481S, BTK^C481R, BTK^T474I, and BTK^T474M, respectively). It is selective for BTK over a panel of 287 additional kinases at 1 µM. Fenebrutinib inhibits anti-IgM antibody-induced BTK phosphorylation in B cells (IC₅₀ = 3.1 nM), as well as anti-IgM- or CD40L-induced proliferation of B cells (IC₅₀s = 1.2 and 1.4 nM, respectively). In vivo, Fenebrutinib (0.06-16 mg/kg) reduces ankle thickness and cartilage damage in a rat model of collagen-induced arthritis.

WARNING This product is not for human or veterinary use.